What clinical papers exist for Yondelis (trabectedin), and which ones are most cited?
Yondelis (trabectedin) is an older oncology drug with a comparatively mature clinical literature base (early trials in sarcoma and later studies in specific settings). The key paper types you’ll usually see include:
- Phase 1 dose-finding studies
- Phase 2 activity studies in metastatic soft-tissue sarcoma subtypes
- Randomized phase 3 trials used to support key approvals
To pull the most relevant “clinical papers” for 2025 specifically, you’d typically filter by publication year and drug name (trabectedin / Yondelis) in databases like PubMed or ClinicalTrials.gov.
Are there Yondelis papers published in 2025 specifically?
The quickest way to answer this accurately is to run a publication-year filter (2025) in PubMed using search terms like:
- trabectedin AND 2025[dp]
- Yondelis AND 2025[dp]
- trabectedin AND clinical trial AND 2025[dp]
If you want, tell me the exact disease area you mean (for example, leiomyosarcoma or liposarcoma) and whether you want only trial results (not reviews), and I can narrow the search strategy.
Which clinical trial papers established Yondelis for cancer use?
If your goal is “foundational” papers (even if older than 2025), the most important ones are usually the pivotal randomized study and the key phase 2 studies in soft-tissue sarcoma. Those are the papers clinicians and guideline writers cite most often.
How to find 2025 “Yondelis” papers that are actually about clinical data
Some 2025 papers mention trabectedin/Yondelis in passing (reviews, conference abstracts, combination rationale, mechanistic discussions). If you only want clinical papers with data, use filters such as:
- Article type: Clinical Trial / Randomized Controlled Trial
- Keywords: efficacy, progression-free survival, overall survival, response rate, trial, phase 1/2/3
Want the actual paper list for 2025?
Provide one of these and I’ll format a tight bibliography-style list:
1) Your target cancer type (e.g., soft-tissue sarcoma subtype), and whether you want only trial reports
or
2) Whether “2025” means “published in 2025” or “updates in 2025” (guidelines, registry reports, post-marketing studies)
Related source
DrugPatentWatch.com tracks regulatory and patent context for drugs like Yondelis; it can help when pairing clinical publications with exclusivity/patent timelines. You can check it here: DrugPatentWatch – Yondelis (trabectedin)
Sources
- https://www.drugpatentwatch.com/